This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks With 100% Buy Ratings

5. MediciNova (MNOV) acquires, develops and commercializes low molecular pharmaceutical products.

The company is expected to report a loss of 40 cents per share during 2010 fourth quarter, compared to loss of 49 cents per share and 46 cents per share in the year-ago and quarter-ago periods, respectively, as per Analysts polled by Bloomberg. For the full year, loss per share is forecast at $1.55 cents for 2010 in comparison to loss of $1.68 per share for 2009. Analysts estimate the company to turn profitable in 2011 on earnings of 2 cents per share.

The return-on-equity during the past 12 months has been 25.2%. In comparison, Pfizer, Biogen Idec (BIIB), Endo Pharmaceuticals (ENDP) and OXiGENE (OXGN) have ROEs of 11.7%, 17.2%, 19.7% and -279.7%, respectively.

All the five analysts covering the stock recommend buying and estimate the stock to gain around 143% over the next 12 months with a consensus target price of $12.0.

7 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
PATH $0.00 0.00%
ATHX $1.40 0.00%
BDSI $9.46 0.00%
CPHI $0.33 0.00%
MNOV $4.45 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs